Daily highlight in breast cancer, early stage
Reported by Dr Caroline Duhem, Centre Hospitalier de Luxembourg, Luxembourg
Mounting evidence indicates a connection between breast cancer risk and outdoor air pollution, a link previously established for lung cancer. However, establishing this association for breast cancer has been challenging due to inconsistent data primarily focused on residential air pollution.
To investigate this further, the French E3N cohort (1999-2011) was analyzed, examining the long-term exposure to air pollutants such as nitrogen dioxide (NO2) and various particulate matter (PM) both at residences and workplaces concerning breast cancer risk. The analysis unequivocally demonstrated an elevated risk of breast cancer associated with air pollution. This finding holds significant implications, especially in environments plagued by air pollution. It could lead to targeted preventive strategies for high-risk individuals, similar to those used in lung cancer prevention, as underlying mechanisms become clearer through histological studies.
Physical activity (PA) is widely recognized for its pivotal role in breast cancer prevention and its benefits for patients, reducing recurrence risk and enhancing survival rates and quality of life. Despite its known advantages, integrating PA into breast cancer patients’ routines presents a challenge. The DISCO trial aimed to evaluate the effectiveness of two 6-month PA interventions during adjuvant breast cancer treatment. These interventions combined patient education with an online program and a connected device for activity tracking, to achieve a minimum of 150 minutes of vigorous activity per week. In this randomized trial involving over 400 patients, the RPAQ global score was assessed at baseline, 6 months, and 12 months. The results indicated that the interventions increased PA at the 6-month mark, a change sustained in 90% of patients at the 12-month follow-up. Notably, regardless of the approach—whether face-to-face support or digital methods—both contributed significantly to enhancing PA levels in these patients.
Additionally, the NATALEE trial demonstrated the superiority of ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) over treatment solely involving NSAI. Specifically, the results presented here focus on invasive disease-free survival (iDFS) within clinically relevant subgroups after 27 months, providing preliminary insights. Across all subgroups, categorized by menopausal status, age, anatomic stage, nodal status, and KI-67, the combined ribociclib and endocrine treatment in the adjuvant setting exhibited a significant iDFS benefit.
References:
Fervers B. – Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011. ESMO2023 – 238MO
Fervers B. – Connected device and therapeutic patient education to promote physical activity among women with localized breast cancer: results from the DISCO randomized trial. ESMO2023 – LBA22
Chen H. – Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials. ESMO2023 – 239MO
Goetz M. – Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). ESMO2023 – 240MO
Bardia A. – Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). ESMO2023 – LBA23
Fredriksson I. – Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020. ESMO2023 – 241MO
Miglietta F. – Association of tumour-infiltrating lymphocytes (TILs) with Recurrence Score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC) – a translational analysis of four prospective multicentric studies. ESMO2023 – 242MO
Gluz O. – Multiparametric prognostic score in early HR+/HER2- breast cancer: impact of Recurrence Score, clinical-pathological factors, gene mutations and histology. ESMO2023 – LBA24
Kuerer H. – Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial. ESMO2023 – 243MO
Fervers B. – A Phase II Trial Targeting Disseminated Dormant Tumor Cells with Hydroxychloroquine, Everolimus or the Combination to Prevent Recurrent Breast Cancer (“CLEVER”). ESMO2023 – 244MO
You may also be interested in:
With the educational support of:
 |
 |
 |